CD22 and neoplasm: However, unlike CD19, the development of resistance to CD22-directed therapies has been associated with the selection of tumor subclones with low (but detectable) CD22 protein expression rather than the acquisition of CD22 coding mutations or modulation of CD22 mRNA expression or splicing (Figure 2) (Fry et al. 2018).